Theralase Technologies Inc. (TSXV:TLT)
Canada · Delayed Price · Currency is CAD 0.1850
-0.0050 (-2.63%)
Aug 26, 2026, 3:58 PM EST
Theralase Technologies Income Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 0.86 | 0.82 | 1.03 | 1.07 | 1.14 | 0.78 | |
Revenue Growth | -9.61% | -20.99% | -3.45% | -6.00% | 45.85% | -15.98% |
Cost of Revenue | 0.3 | 0.31 | 0.48 | 0.51 | 0.51 | 0.47 |
Gross Profit | 0.56 | 0.51 | 0.55 | 0.56 | 0.63 | 0.31 |
Selling, General & Admin | 2.14 | 2.23 | 2.09 | 2.17 | 1.58 | 1.93 |
Research & Development | 2.14 | 2.45 | 2.75 | 2.98 | 4.28 | 2.92 |
Operating Expenses | 4.28 | 4.68 | 4.84 | 5.16 | 5.86 | 4.85 |
Operating Income | -3.72 | -4.18 | -4.29 | -4.59 | -5.23 | -4.54 |
Interest Expense | -0.05 | -0.04 | -0.02 | -0.03 | -0.02 | -0.01 |
Interest & Investment Income | 0.08 | 0.08 | 0.07 | 0.05 | 0.03 | 0.02 |
Currency Exchange Gain (Loss) | 0.01 | 0.02 | -0.01 | 0 | -0.03 | -0.02 |
EBT Excluding Unusual Items | -3.68 | -4.12 | -4.26 | -4.57 | -5.25 | -4.54 |
Legal Settlements | - | - | - | - | 0.01 | 0.13 |
Pretax Income | -3.68 | -4.12 | -4.26 | -4.57 | -5.24 | -4.41 |
Net Income | -3.68 | -4.12 | -4.26 | -4.57 | -5.24 | -4.41 |
Net Income to Common | -3.68 | -4.12 | -4.26 | -4.57 | -5.24 | -4.41 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 257 | 253 | 240 | 220 | 208 | 204 |
Shares Outstanding (Diluted) | 257 | 253 | 240 | 220 | 208 | 204 |
Shares Change | 5.24% | 5.44% | 9.14% | 5.79% | 1.79% | - |
EPS (Basic) | -0.01 | -0.02 | -0.02 | -0.02 | -0.03 | -0.02 |
EPS (Diluted) | -0.01 | -0.02 | -0.02 | -0.02 | -0.03 | -0.02 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -3.16 | -3.33 | -3.37 | -4.11 | -5.17 | -4.13 |
Free Cash Flow Per Share | -0.01 | -0.01 | -0.01 | -0.02 | -0.03 | -0.02 |
Gross Margin | 65.07% | 62.11% | 53.61% | 52.52% | 55.17% | 39.70% |
Operating Margin | -433.40% | -511.39% | -414.96% | -429.25% | -459.48% | -581.77% |
Profit Margin | -429.11% | -504.71% | -411.84% | -427.06% | -459.81% | -565.06% |
Free Cash Flow Margin | -368.66% | -408.43% | -326.11% | -384.01% | -454.37% | -529.21% |
EBITDA | -3.55 | -4 | -4.11 | -4.4 | -4.99 | -4.32 |
D&A For EBITDA | 0.17 | 0.17 | 0.18 | 0.19 | 0.24 | 0.22 |
EBIT | -3.72 | -4.18 | -4.29 | -4.59 | -5.23 | -4.54 |
Advertising Expenses | - | 0.02 | 0.03 | 0.02 | 0.02 | 0.05 |